The Global Influenza Vaccines Market is anticipated to Witness High Growth Owing to Increased Government Support and Initiatives

Pharmaceuticals

The global influenza vaccines market is estimated to be valued at US$ 7,161.38 billion in 2024 and is expected to exhibit a CAGR of 33% over the forecast period of 2024 to 2031. Influenza vaccines help to prevent the spread of influenza and flu among populations worldwide. Influenza viruses can potentially cause severe illness and even lead to death. Therefore, governments across various countries actively promote annual flu vaccination programs to safeguard public health. Increased government support through funding, subsidy programs, and strengthening of immunization services has boosted the uptake of influenza vaccines in recent years.

Key Takeaways

Key players operating in the influenza vaccines market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc. Major players are investing heavily in R&D activities to develop advanced influenza vaccines with enhanced efficacy.

The global Influenza Vaccines Market Demand offers significant growth opportunities owing to rising investments in vaccine development and production by both public and private organizations. Additionally, increasing access to vaccines in developing nations through global immunization programs will further aid the market expansion.

Key players are strategizing global expansion of their influenza vaccine portfolios through collaborations, partnerships, and acquisitions. For instance, in 2023, Sanofi acquired FluGen to strengthen its influenza vaccine pipeline and development capabilities. Such initiatives allow companies to broaden their geographic presence.

Market Drivers and Restraints

One of the major drivers for the influenza vaccines market is the growing prominence of viral disease prevention programs worldwide. The World Health Organization (WHO) recommends annual influenza vaccination for high-risk groups like pregnant women, elderly population, and those with co-morbidities. Strong advocacy by WHO for vaccination is positively influencing the market.

However, high R&D expenditure and regulatory requirements associated with vaccine development may impede the market growth. Frequent mutation of influenza viruses also poses challenges for scientists to develop multivalent and broad-spectrum vaccines with long-term effectiveness. Stringent safety testing prolongs the product approval timelines as well. These factors increase the production costs, thereby acting as a key market restraint.

Segment Analysis

The Influenza Vaccines Market Size And Trends is segmented based on type, technology, age group, route of administration and end user. The high dose vaccines sub segment dominates the type segment as it provides better immunogenic response in the elderly population compared to standard dosage vaccines.

By technology, the egg-based vaccines sub segment holds a significant share as most of the currently available influenza vaccines use chicken eggs for vaccine production however cell-based and recombinant technology sub segments are growing at a faster rate owing to their ability to offer advantages like better production yield and scalability.

When segmented by age group, the pediatric vaccines sub segment dominates due to mandatory vaccination policies in many countries for children. However, the adult segment is expected to witness high growth driven by increasing disease awareness.

The intramuscular route holds the largest share under route of administration segment due to ease of self-administration while nasal spray vaccines sub segment show faster growth rates.

Hospitals contribute the highest revenue under end user segment as they are the primary point of contact for vaccination services. Retail pharmacies sub segment is estimated to grow at a promising rate due to increasing self-administration of flu shots.

Global Analysis

When analyzed geographically, North America currently dominates the global influenza vaccines market and is expected to continue its dominance over the forecast period. This can be attributed to factors such as well-established healthcare infrastructure, conducive reimbursement policies and greater public and private investments for research and development of novel influenza vaccines in the region.

On the other hand, Asia Pacific is anticipated to exhibit the fastest growth over the forecast period in global influenza vaccines market supported by aspects like vast target patient population, growing demand for wider variety of vaccines, greater numbers of vaccine administration campaigns and rising healthcare spending in many APAC countries especially China and India.

Europe holds significant market share and is expected to grow moderately driven by collaboration between private organizations and public health authorities to improve vaccination coverage in the region. Latin America and Middle East & Africa are likely to see steady market expansion during the forecast period.

Get More Insights On, Influenza Vaccines Market

Explore More Related Article On, Chemiluminescence Immunoassay Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

#Influenza Vaccines Market

Submitted 12 months 4 days ago by Sachin CMI.